NCT07318129 Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
| NCT ID | NCT07318129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Glostrup University Hospital, Copenhagen |
| Condition | Relapsing Remitting Multiple Sclerosis (RRMS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2028-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2026-01-26 with a primary completion date of 2028-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Eligibility Criteria
Inclusion Criteria: * Women and men ≥18 and ≤65 years of age * Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates) * Routinely treated and monitored for MS * Speak and read Danish * Deemed physically and mentally able to participate in this study Exclusion Criteria: * Active malignancy * Diagnosis of Crohn's disease and ulcerative colitis * Other comorbidities deemed to be relevant * Haematopoietic stem cell transplantation * Current or past treatment with non-MS related treatments deemed to be relevant * Pregnancy or lactation * People with MR contraindications: * Severe claustrophobia * Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
Contact & Investigator
Jette Lautrup Frederiksen, MD, dr.med, professor
✉ jette.lautrup.battistini@regionh.dk📞 +4538633041
Jette Lautrup Frederiksen, MD, dr.med, professor
PRINCIPAL INVESTIGATOR
Copenhagen University Hospital, Rigshospitalet-Glostrup
Frequently Asked Questions
Who can join the NCT07318129 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Relapsing Remitting Multiple Sclerosis (RRMS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07318129 currently recruiting?
Yes, NCT07318129 is actively recruiting participants. Contact the research team at jette.lautrup.battistini@regionh.dk for enrollment information.
Where is the NCT07318129 trial being conducted?
This trial is being conducted at Glostrup Municipality, Denmark.
Who is sponsoring the NCT07318129 clinical trial?
NCT07318129 is sponsored by Glostrup University Hospital, Copenhagen. The principal investigator is Jette Lautrup Frederiksen, MD, dr.med, professor at Copenhagen University Hospital, Rigshospitalet-Glostrup. The trial plans to enroll 220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.